LITERATURA

1. Broďák M. Léčiva používaná k terapii dysfunkcí dolních močových cest, in: Suchopár J et al. Compendium. Léčiva používaná v podmínkách ČR. 2018:677-690.
2. Oefelein MG.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011;34(9):733-754.
3. Prokeš M, Suchopár J. Anticholinergní léčiva a kumulace jejich nežádoucích účinků u seniorů. Med. Praxi. 2020;17(3): 182-189.
4. Boustani MA, Campbell NL, Munger S, et al. Impact of anticholinregics: a review and practical application. Aging Health. 2008;4(3):311-320.
5. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.
6. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50(2):317-326.
7. Coupland CA, Trevor-Hill, Dening T, et al. Anticholinergic drug exposure and the risk of dementia. A nestad case-control study. JAMA Intern Med. 2019;179(8):1084-1093.
8. Rube TE, Scorcheville A, Londos E, et al. Development of the Swedish anticholinergic burden scale (Swe-ABS). Drugs. 2023;83(4):315-340.
9. Bishara D, Perera G, Harwood D, et al. Centrally Acting Anticholinergic Drugs Used for Urinary Conditions Associated with Worse Outcomes in Dementia. J Am Med Dir Assoc. 2021;22(12):2547-2552.
10. Matta R, Gomes T, Juurlink D, et al. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. Eur Urol Focus. 2022;8(5):1433-1440.
11. Özmen N, Yiginer Ö, Ün H, Bicakci B. Frequently occurring torsades de pointes attacks in an old patient on solifenacin therapy and management strategy. Anatol J Cardiol. 2015;15(4):342-3.
12. Asajima H, Sekiguchi Y, Matsushima S, et al. QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol. 2008;66(6):896-897.
13. DrugBank®. DB06702 [Internet]. [cited 2025 Feb 26]. Available from: https://go.drugbank.com/drugs/(vstup 26.2.2025).
14. Woosley RL, Heise CW, Gallo T, et al. QTdrugs List [Internet]. CredibleMeds®; Tucson, AZ, AZCERT; Available from: www.CredibleMeds.org [cited 2025 Feb 25].
15. Suchopár J, et al. Lékové interakce v urologii – na co si dát pozor. Urol. Praxi. 2020;21(2):80-86.
16. Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol. 1996;41(1):73-75.
17. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol. 2005;45(9):1038-1047.
18. Breuel HP, Mürtz G, Bondy S, et al. Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung. 1993;43(4):461-464.
19. Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. Int J Clin Pharmacol Ther. 2011;49(6):353-365.
20. Suchopár J, et al. Léky prodlužující QT interval, in: Suchopár J, et al: Lékové interakce. Obecné aspekty lékových interakcí, první díl B. DrugAgency® a. s. 2023:725-750.
21. Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol. 1997;52(5):403-406.
22. Swart PJ, Krauwinkel WJJ, Smulders RA, et al. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. Basic Clin Pharmacol Toxicol 2006;99(1):33-36.
23. Abebe BT, Weiss M, Modess C, et al. Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects. J Clin Pharmacol. 2019;59(10):1319-1330.
24. Astellas Pharma US, Inc. Vesicare® (solifenacin) – Full prescribing information [Internet]. 2020 May [cited 2025 Feb 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021518s017lbl.pdf.
25. AbbVie Inc. Enablex® (darifenacin) – Full prescribing information [Internet]. 2021 Jul [cited 2025 Feb 25. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021513s017lbl.pdf a Clinical Pharmacology Biopharmaceutics Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf.
26. Malhotra B, Sachse R, Wood N. Evaluation of drug--drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009;65(6):551-560.
27. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31. https://bmcgeriatr.biomedcentral.com/ articles/10.1186/s12877–015–0029–9.
28. Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol. 2016;69(2):311-323.
29. Park JS, Choi SB, Jang WS, et al. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study. Eur Urol Focus. 2024;10(2):306-314.
30. Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696-706.
31. Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‚add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open--label study in Japan (MILAI study). BJU Int. 2015;116(4):612-622.
32. Katoh T, Igawa Y, Yamaguchi O, et al. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Low Urin Tract Symptoms. 2020;12(1):68-80.
33. Lee J, Moy S, Meijer J, et al. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig. 2013;33(6): 429-440.
34. Konishi K, Minematsu T, Nagasaka Y, Tabata K. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. Xenobiotica. 2019;49(8): 912-921.
35. Konishi K, Minematsu T, Nagasaka Y, Tabata K. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Biopharm Drug Dispos. 2019;40(5-6):176-187.
36. Krauwinkel W, et al. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014;39(1):43-52.
37. Groen-Wijnberg M, van Dijk J, Krauwinkel W, et al. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Eur J Drug Metab Pharmacokinet. 2017;42(3):417-429.
38. Lin J, Goosen TC, Tse S, et al. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron. J Clin Pharmacol. 2019;59(11):1505-1518.
39. U. S. Food and Drug Administration. Gemtesa® (vibegron) – clinical pharmacology and biopharmaceutics review(s) [Internet]. Urovant; 2020 Dec [cited 2025 Feb 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213006Orig1s000ClinPharmR.pdf.
40. Ritchey ME, Wang J, Young JC, et al. CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis. Drugs Real World Outcomes. 2023;10(1):119-129.
41. Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183-190.
42. Okita Y, Shimomura Y, Komukai S, et al. Risks of Dementia Associated With Anticholinergic Medication Compared to Beta-3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study. Int J Geriatr Psychiatry. 2025;40(1):e70036.
43. Trbovich M, Romo T, Polk M, et al. The treatment of neurogenic lower urinary tract dysfunction in persons with spinal cord injury: An open label, pilot study of anticholinergic agent vs. mirabegron to evaluate cognitive impact and efficacy. Spinal Cord Ser Cases. 2021;7(1):50.